Technology ID
E-281-2013-0

Novel Primate T-cell Lymphotropic Viruses (HTLV, STLV) for Development of Diagnostics, Therapeutics, Research Tools, and Vaccines

Linked ID
TAB-2725
Inventors
Donald Burke (Johns Hopkins University)
Mpoudi Eitel ()
Nathan Wolfe (Johns Hopkins University)
Thomas Folks (CDC)
Walid Heneine (CDC)
William Switzer (CDC)
Lead Inventors
Donald Burke (Johns Hopkins University)
Co-Inventors
Mpoudi Eitel ()
Nathan Wolfe (Johns Hopkins University)
Thomas Folks (CDC)
Walid Heneine (CDC)
William Switzer (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
  • Early-stage
  • In vitro data available
Applications
Research Materials
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Development of HTLV diagnostics
  • Simian/human T-cell lymphotropic virus research
  • Zoonosis surveillance
  • Vaccine design and development
CDC researchers have isolated and characterized the novel primate T-lymphotropic viruses denoted human T-lymphotropic viruses 3 and 4 (HTLV-3 and HTLV4), that are believed to have resulted from cross-species transmission at some point in the past. It has been previously established that HTLV-1 causes adult T cell leukemia and other inflammatory diseases; HTLV-2 is considered less pathogenic than HTLV-1 and has been associated with a neurologic disease similar to HTLV-1-associated myelopathy. At present, the human pathologies of HTLV-3 and HTLV-4 are yet uncharacterized, but have been identified as infecting rural Central African hunters who have much greater risk of contact with non-human primates, sometimes infected with simian T-lymphotropic viruses (STLVs). As HTLV infected individuals from rural, isolated populations have increasing contact with their urban brethren, there is increased potential for the rapid spread of new viral zoonotic-originating pathogens, much like the theorized "bushmeat" origins of HIV. There is a present and unmet need for increased surveillance, study, and preventative therapeutics directed towards mitigating the public health impact of these viruses. This CDC developed technology provides methods and tools to that end.
Competitive Advantages
  • Provides tremendous opportunity for phylogenetic, clinical and epidemiological investigations of HTLV and STLV
  • Facilitates monitoring of viral diversity and study of zoonotic disease transmission
  • Provides tools needed to address and mitigate a newly emergent blood-borne disease before widespread, regional/global viral dissemination occurs

Request More Info

Licensing Contact